1. Field of the Invention
The present invention is directed to biopolymer photonic crystals and methods for manufacturing such photonic crystals.
2. Description of Related Art
The field of optics is well established. Some subfields of optics include diffractive optics, micro-optics, photonics, and guided wave optics. Various optical devices have been fabricated in these and other subfields of optics for research and commercial application. For example, common optical devices include diffraction gratings, photonic crystals, optofluidic devices, waveguides, and the like.
Photonic crystals are periodic dielectric or metallo-dielectric structures that define allowed and forbidden electronic energy bands. In this fashion, photonic crystals are designed to affect the propagation of electromagnetic (EM) waves in the same manner in which the periodic potential in a semiconductor crystal affects electron motion.
Photonic crystals include periodically repeating internal regions of high and low dielectric constants. Photons propagate through the structure based upon the wavelength of the photons. Photons with wavelengths of light that are allowed to propagate through the structure are called “modes”. Photons with wavelengths of light that are not allowed to propagate are called “photonic band gaps”. The structure of the photonic crystals define allowed and forbidden electronic energy bands. The photonic band gap is characterized by the absence of propagating EM modes inside the structures in a range of wavelengths and may be either a full photonic band gap or a partial photonic band gap, and gives rise to distinct optical phenomena such as inhibition or enhancement of spontaneous emission, spectral selectivity of light, or spatial selectivity of light. Such structures can be used for high-reflecting omni-directional mirrors and low-loss waveguides. Photonic crystals are attractive optical devices for controlling and manipulating the flow of light. Photonic crystals are also of interest for fundamental and applied research and are being developed for commercial applications. Two-dimensional periodic photonic crystals are being used to develop integrated-device applications.
Advances in micro-technology and nanotechnology have led to the miniaturization of a number of devices. Applied scientists and researchers continue to attempt to engineer control matter on the atomic and molecular scale and to build devices in that size range. These scientists drawing from applied physics, materials science, interface and colloid science, device physics, chemistry, and engineering disciplines to bring existing technology to the nanoscale.
Lithographic techniques serve to facilitate development of nanoscale devices by selectively removing portions of thin films or substrates. Scanning probe lithography incorporates a microscopic stylus that is mechanically moved across a surface to form new patterns on the film. The new patterns are formed by mechanically deforming the surface of the film using nanoimprint lithography or by transferring a chemical to the surface of the film.
Dip Pen Nanolithography® (DPN) is a scanning probe lithography technique that may use an atomic force microscope tip to transfer molecules to the film surface using a solvent meniscus. This technique allows surface patterning on scales of under 100 nanometers. DPN is the nanotechnology analog of a quill pen, where the tip of an atomic force microscope cantilever acts as a “pen,” which is coated with a chemical compound or a mixture acting as an “ink,” and put in contact with a substrate, the “paper.”
DPN enables direct deposition of nanoscale materials onto a substrate in a flexible manner. The vehicle for deposition can include pyramidal scanning probe microscope tips, hollow tips, and even tips on thermally actuated cantilevers.
Photonic crystals and other optical devices are fabricated using various methods, depending on the application and optical characteristics desired. However, these optical devices, and the fabrication methods employed in their manufacture, generally involve significant use of non-biodegradable materials. For example, glass, fused silica, or plastic are commonly used in optical devices. Such materials are not biodegradable, and remain in the environment for extended period of time after the optical devices are removed from service and discarded. Of course, some of the materials can be recycled and reused. However, recycling also requires expenditure of natural resources, and adds to the environmental costs associated with such materials.
Therefore, there exists an unfulfilled need for optical devices such as photonic crystals that minimize the negative impact to the environment. In addition, there exists an unfulfilled need for photonic crystals that provide additional functional features that are not provided by conventional photonic crystals.
In view of the foregoing, objects of the present invention are to provide novel photonic crystals and methods for manufacturing such photonic crystals.
One aspect of the present invention is to provide photonic crystals made from a biopolymer.
Another aspect of the present invention is to provide a method for manufacturing such biopolymer photonic crystals.
One advantage of the present invention is in providing photonic crystals that minimize the negative impact to the environment.
Another advantage of the present invention is in providing photonic crystals that are biocompatible.
Yet another advantage of the present invention is in providing photonic crystals that have additional functional features that are not provided by conventional photonic crystals.
In the above regard, inventors of the present invention recognized that biopolymers, and especially silk proteins, present novel structure and resulting functions. For example, from a materials science perspective, silks spun by spiders and silkworms represent the strongest and toughest natural fibers known and present various opportunities for functionalization, processing, and biocompatibility. Over five millennia of history accompany the journey of silk from a sought-after textile to a scientifically attractive fiber. As much as its features had captivated people in the past, silk commands considerable attention in this day and age because of its strength, elasticity, and biochemical properties. The novel material features of silks have recently been extended due to insights into self-assembly and the role of water in assembly. These insights, in turn, have led to new processing methods to generate hydrogels, ultrathin films, thick films, conformal coatings, three dimensional porous matrices, solid blocks, nanoscale diameter fibers, and large diameter fibers.
Silk-based materials achieve their impressive mechanical properties with natural physical crosslinks of thermodynamically stable protein secondary structures also known as beta sheets (β-sheets). Thus, no exogenous crosslinking reactions or post process crosslinking is required to stabilize the materials. The presence of diverse amino acid side chain chemistries on silk protein chains facilitates coupling chemistry for functionalizing silks, such as with cytokines, morphogens, and cell binding domains. There are no known synthetic or biologically-derived polymer systems that offer this range of material properties or biological interfaces, when considering mechanical profiles, aqueous processing, room-temperature processing, ease of functionalization, diverse modes of processing, self-forming crosslinks, biocompatibility, and biodegradability.
While no other biopolymer or synthetic polymer can match the range of features outlined above for silk, some other polymers that exhibit various properties similar or analogous to silk have been identified by the inventors of the present invention. In particular, other natural biopolymers including chitosan, collagen, gelatin, agarose, chitin, polyhydroxyalkanoates, pullan, starch (amylose amylopectin), cellulose, hyaluronic acid, and related biopolymers have been identified. In view of the above noted features of biopolymers and of silk in particular, the present invention provides novel photonic crystals, and methods for manufacturing such photonic crystals made from a biopolymer.
In one embodiment of the present invention, silk is substituted for dielectrics or metallo-dielectrices to afford fabrication of biophotonic crystals (BPCs). In accordance with one aspect of the present invention, a method of manufacturing a biopolymer photonic crystal is provided. In one embodiment, the method includes providing at least one biopolymer film with nanopatterned features on a surface thereof, which can be utilized as a photonic crystal. In a preferred embodiment, the method includes providing a plurality of nanopatterned biopolymer films, and stacking the plurality of nanopatterned biopolymer films together. In this regard, the plurality of nanopatterned biopolymer films may be oriented so that adjacent biopolymer films have differing orientations. The method may further include binding the stacked plurality of nanopatterned biopolymer films to each other.
In accordance with one embodiment, the nanopatterned biopolymer films comprise silk, chitosan, collagen, gelatin, agarose, chitin, polyhydroxyalkanoates, pullan, starch (amylose amylopectin), cellulose, hyaluronic acid, and related biopolymers. In another embodiment, the method also includes embedding an organic material in the nanopatterned biopolymer film. For example, the organic material may be embedded in the nanopatterned biopolymer films and/or may be coated on a surface of the nanopatterned biopolymer films. Other materials may be embedded in the biopolymer or used in the coating, including biological materials or other materials depending upon the type of biopolymer photonic crystal desired. The devices may be processed within the biopolymer film, coupled to the surface of the device, or sandwiched within layers to further provide recognition and response functions. The organic material may be red blood cells, horseradish peroxidase, phenolsulfonphthalein, nucleic acid, a dye, a cell, an antibody, enzymes, for example, peroxidase, lipase, amylose, organophosphate dehydrogenase, ligases, restriction endonucleases, ribonucleases, DNA polymerases, glucose oxidase, laccase, cells, viruses, proteins, peptides, small molecules (e.g., drugs, dyes, amino acids, vitamins, antioxidants), DNA, RNA, RNAi, lipids, nucleotides, aptamers, carbohydrates, chromophores, light emitting organic compounds such as luciferin, carotenes and light emitting inorganic compounds (such as chemical dyes), antibiotics, antifungals, antivirals, light harvesting compounds such as chlorophyll, bacteriorhodopsin, protorhodopsin, and porphyrins and related electronically active compounds, or a combination thereof can be added.
In accordance with one preferred embodiment, the step of providing a biopolymer film or a nanopatterned biopolymer film includes providing a biopolymer, processing the biopolymer to yield a biopolymer matrix solution, providing a substrate, casting the matrix solution on the substrate, and drying the biopolymer matrix solution to form a solidified biopolymer film. In such an embodiment, the solidified biopolymer film may be annealed and additionally dried. In addition, the annealing of the solidified biopolymer film may be performed in a vacuum environment, and/or a water vapor environment.
Moreover, the substrate may include a nanopatterned surface so that when the biopolymer matrix solution is cast on the nanopatterned surface of the substrate, the solidified biopolymer film is formed with a surface having a nanopattern thereon. In this regard, the substrate may be an optical device such as a lens, a microlens array, an optical grating, a pattern generator, a beam reshaper, or other suitable arrangement of geometrical features such as holes, pits, and the like. In one preferred method, the biopolymer matrix solution is an aqueous silk fibroin solution having approximately 1.0 wt % to 30 wt % silk, inclusive.
In accordance with another embodiment of the method of the present invention, the at least one nanopatterned biopolymer film is provided by machining a nanopattern on the solidified biopolymer film, for example, machining an array of holes and/or pits. This machining of the nanopattern on the solidified biopolymer film may be performed using an appropriate fabrication method. For example, such machining may be performed using soft lithography techniques and/or a laser, for example, via femtosecond laser pulses generated by the laser.
In accordance with another embodiment of the present invention, a method of manufacturing a biopolymer photonic crystal is provided including, providing a biopolymer, processing the biopolymer to yield a biopolymer matrix solution, providing a substrate, casting the matrix solution on the substrate, and drying the biopolymer matrix solution to form a solidified biopolymer film. In the preferred embodiment, a plurality of substrates are provided and the matrix solution is cast on the substrates and dried to provide a plurality of biopolymer films, which are then, stacked together to form the biopolymer photonic crystal. In accordance with one embodiment, the method includes machining a nanopattern on the at least one solidified biopolymer film. In another embodiment, the substrate includes a nanopatterned surface, and the biopolymer matrix solution is cast on the nanopatterned surface of the substrate so that the solidified biopolymer film is formed with a surface having a nanopattern thereon.
In accordance with another aspect of the present invention, a photonic crystal is provided which is made of at least one biopolymer film having a nanopatterned surface thereon. In one preferred embodiment, the photonic crystal includes a plurality of nanopatterned films that are stacked together, the films being made of a biopolymer. In one embodiment, the plurality of nanopatterned biopolymer films may be oriented so that adjacent biopolymer films have differing orientations. In another embodiment, the stacked nanopatterned films are bound together. Preferably, the biopolymer is silk, chitosan, collagen, gelatin, agarose, chitin, polyhydroxyalkanoates, pullan, starch (amylose amylopectin), cellulose, hyaluronic acid, and related biopolymers
In accordance with another embodiment, the biopolymer photonic crystal includes an embedded organic material such as red blood cells, horseradish peroxidase, phenolsulfonphthalein, nucleic acid, a dye, a cell, an antibody, enzymes, for example, peroxidase, lipase, amylose, organophosphate dehydrogenase, ligases, restriction endonucleases, ribonucleases, DNA polymerases, glucose oxidase, laccase, cells, viruses, proteins, peptides, small molecules (e.g., drugs, dyes, amino acids, vitamins, antioxidants), DNA, RNA, RNAi, lipids, nucleotides, aptamers, carbohydrates, chromophores, light emitting organic compounds such as luciferin, carotenes and light emitting inorganic compounds (such as chemical dyes), antibiotics, antifungals, antivirals, light harvesting compounds such as chlorophyll, bacteriorhodopsin, protorhodopsin, and porphyrins and related electronically active compounds, or a combination thereof.
These and other advantages and features of the present invention will become more apparent from the following detailed description of the preferred embodiments of the present invention when viewed in conjunction with the accompanying drawings.
Initially, it is noted that in view of the superior functional characteristics and processability that were noted above, biopolymer photonic crystals of the present invention are described herein below as being implemented with silk, which is biocompatible and biodegradable. In this regard, the silk utilized was silkworm silk. However, there are many different silks, including spider silk, transgenic silks, and genetically engineered silks, variants and combinations thereof and others, that may alternatively be used in accordance with the present invention to manufacture a biopolymer photonic crystal in accordance with the present invention.
In addition, other biodegradable polymers may be used instead of silk. For example, some biopolymers, such as chitosan, exhibit desirable mechanical properties, can be processed in water, and forms generally clear films for optical applications. Other biopolymers, such as collagen, cellulose, chitin, hyaluronic acid, amylose, and the like may alternatively be utilized in specific applications, and synthetic biodegradable polymers such as polylactic acid, polyglycolic acid, polyhydroxyalkanoates, and related copolymers may also be selectively used. Some of these polymers are not easily processable in water. Nonetheless, such polymers may be used by themselves, or in combinations with silk, and may be used to manufacture biopolymer photonic crystals for specific applications.
It should be initially noted that the term “nanopatterned” as used herein refers to very small patterning that is provided on a surface of the biopolymer films, the patterning having structural features of a size that can be appropriately measured on a nanometer (nm) scale (that is, 10−9 meters). For example, sizes ranging from 100 nm to a few microns are typical of the patterning used in accord with the present invention.
The optical quality and toughness of silk, and in particular, films made from silk, makes them ideal candidates for use in biocompatible engineered optical devices. In particular, these biocompatible engineered optical devices can then be appropriately structured for processing electromagnetic waves, including visible light wavelengths. Correspondingly, to manufacture biopolymer photonic crystals in accordance with the present invention, optical quality biopolymer films are manufactured with regular pattern structures that have a very fine length scale (nanoscale).
In the above regard,
Thus, in the example of silk, an aqueous silk fibroin solution is processed in step 24, for example, 8.0 wt %, which is used to manufacture the biopolymer films of the biopolymer photonic crystal. Of course, in other embodiments, the solution concentrations may also be varied from very dilute (approximately 1 wt %) to very high (up to 30 wt %) using either dilution or concentration, for example, via osmotic stress or drying techniques. Production of aqueous silk fibroin solution is described in detail in WIPO Publication Number WO 2005/012606 entitled “Concentrated Aqueous Silk Fibroin Solution and Uses Thereof,” which is incorporated by reference.
A substrate is provided in step 26 to serve as a mold in manufacturing the biopolymer film. The aqueous biopolymer matrix solution is then cast on the substrate in step 28. The biopolymer matrix solution is dried in step 30 to transition the aqueous biopolymer matrix solution to the solid phase. In this regard, the aqueous biopolymer matrix solution may be dried for a period of time such as 24 hours, and may optionally be subjected to low heat to expedite drying of the aqueous biopolymer solution. Other drying techniques may also be used such as isothermal drying, roller drying, spray drying, and heating techniques. Upon drying, a biopolymer film is formed on the surface of the substrate. The thickness of the biopolymer film depends upon the volume of the biopolymer matrix solution applied to the substrate.
Once the drying is complete and the solvent of the biopolymer matrix solution has evaporated, the biopolymer film is then optionally annealed in step 32. This annealing step may be performed within a water vapor environment, such as in a chamber filled with water vapor, for different periods of time depending on the material properties desired. Typical time periods may range from two hours to two days, for example, and the optional annealing may also be performed in a vacuum environment. The annealed biopolymer film is then removed from the substrate in step 34 and allowed to dry further in step 36. The film manufactured in the above-described manner can be used as a photonic crystal that is biodegradable. In addition, a plurality of such films can be used in manufacturing a biopolymer photonic crystal in accordance with the method of
Patterned nanostructures can be provided on the biopolymer films, such as the silk films manufactured in the above discussed manner. In one embodiment, the surface of the substrate may be smooth so as to provide a smooth biopolymer film, and a nanopattern may be machined on the surface of the biopolymer film. The nanopattern may be machined using a laser, such as a femtosecond laser, or by other nanopattern machining techniques, including lithography techniques such as photolithography, electron beam lithography, and the like. Using such techniques, nanopattern features as small as 700 nm that are spaced less than 3 μm have been demonstrated as described in further detail below.
In another embodiment, the surface of the substrate itself may have an appropriate nanopattern thereon so that when the solidified biopolymer film is removed from the substrate, the biopolymer film is already formed with the desired nanopattern on a surface thereof. In such an implementation, the substrate may be an optical device such as a nanopatterned optical grating, depending on the nanopattern desired on the biopolymer films. The substrate surfaces may be coated with Teflon™ and other suitable coatings to ensure even detachment after the biopolymer matrix solution transitions from the liquid to the solid phase. The ability of the biopolymer casting method using a nanopatterned substrate for forming highly defined nanopatterned structures in the resultant biopolymer films was verified, and silk films having nanostructures as small as 75 nm and RMS surface roughness of less than 5 nm have been demonstrated.
The measured roughness of cast silk film on an optically flat surface shows measured root mean squared roughness values between 2.5 and 5 nanometers, which implies a surface roughness easily less than λ/50 at a wavelength of 633 nm. Atomic force microscope images of patterned silk diffractive optics show the levels of microfabrication obtainable by casting and lifting silk films off of appropriate molds. The images show definition in the hundreds of nanometer range and the sharpness of the corners indicates the possibility of faithful patterning down to the tens of nanometers.
Experiments were conducted to validate the efficacy of the above-described biopolymer films and the method of manufacturing the biopolymer films that can then be used as photonic crystals, or that can be assembled into a biopolymer photonic crystal. In particular, graph 40 of
Of course, the film properties, such as thickness and biopolymer content, as well as optical features, may be altered based on the concentration of fibroin used in the process, the volume of the aqueous silk fibroin solution deposited, and the post deposition process for drying the cast solution. Accurate control of these parameters is desirable to ensure the optical quality of the resultant biopolymer optical device and to maintain various characteristics of the biopolymer optical device, such as transparency, structural rigidity, or flexibility. Furthermore, additives to the biopolymer matrix solution may be used to alter features of the biopolymer optical device such as morphology, stability, and the like, as with polyethylene glycols, collagens, and the like.
In addition, the unpatterned silk film 44 was also analyzed to determine transparency.
The structural stability and ability to have a nanostructure thereon makes the above-described silk films appropriate for use as a photonic crystal and for use in manufacture of biopolymer photonic crystals. As previously noted, the material properties of silk films are well-suited for patterning on the nanoscale, for example, using soft lithography and laser machining techniques. With appropriate relief masks, silk films may be cast and left to solidify upon the surface and subsequently detached. The silk casting and solidification process allows the formation of highly-defined patterned structures on the nanoscale as described below which enables the production of biopolymer films that can be used for manufacturing biopolymer photonic crystals.
Machining of silk films to provide nanopatterning has been demonstrated using a femtosecond laser, and sub-diffraction limit spot size patterning has been achieved.
In particular, to provide such holes, femtosecond laser pulses from a commercial mode-locked titanium sapphire laser called Tsunami®, available through Spectra Physics Division of Newport Corporation, was utilized with the following specification: t=100 fs; average power=1.1 W; repetition rate=80 MHz; and wavelength=810 nm. The laser pulses were focused by a moderate numerical aperture (NA=0.4) ball lens onto the silk films. The laser beam is elliptical in shape due to an uncompensated astigmatism in the laser cavity. The shape of the beam is not reflected in the holes produced because of the nonlinear nature of the ablation process. As noted, holes 64 of
The above-described method for machining the nanopattern on the surface of the biopolymer film relies on a multi-photon process that uses the ultraviolet absorption of fibroin so that the use of femtosecond lasers in the infrared region machines the surfaces with precision, while using only a portion of the electric-field above threshold. The absorption band centered around 270 nm is a good match for a three-photon process using machining photons at a wavelength of 810 nm. This laser manufacturing ability allows for controlled machining of a nanopattern on the biopolymer films made of silk, much in the way that laser machining has been successful in photomask repair and in multi-photon polymerization. The multi-photon ablation process and the associated multi-photon absorption also allow obtaining of diffraction limited, or sub-diffraction limited, spot sizes in biopolymer films.
As explained above, in accordance with the present invention, the individual biopolymer films that are machined or formed to have nanopatterns thereon are used as building blocks to manufacture three-dimensional biopolymer photonic crystals by stacking the individual biopolymer film layers together. In this regard,
As also explained, the nanopatterning of the biopolymer film may alternatively be integrally formed with the biopolymer film by casting the biopolymer matrix solution on a substrate having the desired nanopattern on its surface. In this regard, holographic diffraction gratings of various line pitches were used as substrates upon which aqueous silk fibroin solution was cast to form the biopolymer film.
Thus, as can be appreciated from the above discussion, manufacturing of a three-dimensional biopolymer photonic crystal is performed in accordance with one embodiment of the present invention by manufacturing and stacking a plurality of nanopatterned biopolymer films together. As explained, the nanopatterning of the biopolymer films can be performed by machining, for example, by laser or by forming the biopolymer films with the nanopatterning integral thereon. These biopolymer films may optionally be bound together, for example, by using small quantities of the aqueous biopolymer matrix solution or by using other substances as described above relative to the embodiment of
Important advantages and functionality can be attained by the biopolymer photonic crystal in accordance with the present invention, whether it is implemented by a single film or by an assembly of stacked films. In particular, the biopolymer photonic crystal can be biologically functionalized by optionally embedding it with one or more organic indicators, living cells, organisms, markers, proteins, and the like. More specifically, the biopolymer photonic crystals in accordance with the present invention may be embedded or coated with organic materials such as red blood cells, horseradish peroxidase, phenolsulfonphthalein, nucleic acid, a dye, a cell, an antibody, as described further in Appendix I, enzymes, for example, peroxidase, lipase, amylose, organophosphate dehydrogenase, ligases, restriction endonucleases, ribonucleases, DNA polymerases, glucose oxidase, laccase, cells, viruses, proteins, peptides, small molecules (e.g., drugs, dyes, amino acids, vitamins, antioxidants), DNA, RNA, RNAi, lipids, nucleotides, aptamers, carbohydrates, chromophores, light emitting organic compounds such as luciferin, carotenes and light emitting inorganic compounds (such as chemical dyes), antibiotics, antifungals, antivirals, light harvesting compounds such as chlorophyll, bacteriorhodopsin, protorhodopsin, and porphyrins and related electronically active compounds, tissues or other living materials, other compounds or combinations thereof. The embedded organic materials are biologically active, thereby adding biological functionality to the resultant biopolymer photonic crystal.
The embedding of the biopolymer photonic crystal with organic materials may be performed for example, by adding such materials to the biopolymer matrix solution used to manufacture the biopolymer films, such as the silk fibroin matrix solution. In the implementation where the biopolymer photonic crystal is manufactured by stacking a plurality of biopolymer films, the photonic crystal can be biologically functionalized by functionalizing of one or more of the biopolymer films. Alternatively, or in addition thereto, such added organic materials can be sandwiched between the biopolymer film layers that make up the biopolymer photonic crystal in such an implementation.
While
The biologically induced variation in the photonic bandgap and spectral selectivity of the resultant biopolymer photonic crystal can be used to determine the presence of particular substances, and biological processes can also be sensitively monitored optically. In particular, such substances may be detected based on the changes in the optical properties of the biopolymer photonic crystal, since the change in spectral selectivity can be correlated to the features of the photonic crystal structure and/or to the organic materials embedded therein. This is especially advantageous in applications where biopolymer photonic crystals are used as sensors to provide recognition and/or response functions.
Correspondingly, as explained, dielectrics and metallo-dielectrics used in conventional photonic crystals can be replaced with silk or with other biopolymers in accordance with the present invention to allow the fabrication of biopolymer photonic crystals. In addition, the present invention may be used to provide customized biopolymer photonic crystals for use as bio-optical filters by allowing the variability of the bandgap or tuning of the biological-bandgaps.
Furthermore, it should also be appreciated that further fabrication of biophotonic bandgap materials and functionalization may be performed by hybridizing the biopolymer photonic crystal of the present invention. For example, the biopolymer photonic crystal and/or biopolymer films constituting the photonic crystal may be deposited with thin metallic layers to provide differing optical characteristics. The bulk index of the biopolymer photonic crystal can be affected in this manner to enhance the contrast factor and to tailor the spectral selectivity. Such hybridized biopolymer photonic crystals may be advantageously used as bioplasmonic sensors, thereby integrating electromagnetic resonance, optics, and biological technologies together in a biocompatible optical device.
As also previously noted, alternative polymers may also be used for fabrication of biopolymer photonic crystals in accordance with the present invention. In this regard,
As can be appreciated from the above discussion, manufacturing of the biopolymer photonic crystal is performed by providing a biopolymer film with a nanopatterned surface thereon to have the desired bandgap or desired partial bandgap, spectral selectivity and/or optical functionality. In the preferred embodiment, manufacturing the biopolymer photonic crystal is performed by manufacturing a plurality of nanopatterned biopolymer films and stacking them to produce a biopolymer photonic crystal that has the desired bandgap, partial bandgap, spectral selectivity, and/or optical functionality. The resultant biopolymer photonic crystal allows manipulation of light via an organic yet mechanically robust optical device, thereby combining the flexibility of embedded optics with the unique versatility of biopolymers. Thus, the biopolymer photonic crystal of the present invention combines (a) the organic nature of biopolymers, such as silk, which is controllably degradable, biocompatible, and structurally strong; (b) the power of diffractive and transmissive optics embedded in an organic matrix; and (c) the creation of biologically active optical elements. As explained above, the biopolymer photonic crystals of the present invention may be biologically activated by incorporating organic material. For example, biologically active complex proteins such as hemoglobin in red blood cells and enzymes such as peroxidase may be used. Correspondingly, the present invention broadens the versatility of optical devices by allowing the direct incorporation of labile biological receptors in the form of peptides, enzymes, cells, antibodies, or related systems, and allows such optical devices to function as biological sensing devices.
The biodegradable biopolymer photonic crystals of the present invention also have the advantage of being naturally biocompatible and being able to undergo degradation with controlled lifetimes. The degradation lifetime of the biopolymer photonic crystals of the present invention can be controlled during the manufacturing process, for example, by controlling the ratio and amount of the solution matrix cast.
As can be appreciated, the biopolymer photonic crystals of the present invention can be readily used in environmental and life sciences where biocompatibility and biodegradability are paramount. For example, the biopolymer photonic crystals as described herein can be unobtrusively used to monitor a natural environment so that the biopolymer photonic crystals can be dispersed in the environment, without the need to retrieve them at a later time, thereby providing novel and useful devices for sensing and detection. In addition, the biopolymer photonic crystals can be used in vivo, for example, implanted in the human body, without a need to retrieve the device at a later time.
The ability to pattern structural proteins on the nanoscale via dip pen nanolithography (DPN) has been described supra. Thus, the biopolymer devices described above may be further downsized to generate chip based arrays in which the patterned substrate serves to generate the overall optical response, while nanoscale wires of silk are written on these patterns with this DPN AFM technique. This provides miniaturized biopolymer optical detectors and devices. In this regard, nanoscale biopolymer devices patterned in a 60 nm matrix may be developed to replicate porous alumina.
The foregoing description of the aspects and embodiments of the present invention provides illustration and description, but is not intended to be exhaustive or to limit the invention to the precise form disclosed. Those of skill in the art will recognize certain modifications, permutations, additions, and combinations of those embodiments are possible in light of the above teachings or may be acquired from practice of the invention. Therefore, the present invention also covers various modifications and equivalent arrangements that fall within the purview of the appended claims.
Materials—Anti-IL-8 monoclonal antibody (IgG1) was purchased from eBioscience, Inc. human polyclonal antibody IgG and human IgG ELISA Quantitation Kit were purchased from Bethyl Laboratories Inc. All other chemicals used in the study were purchased from Sigma-Aldrich (St. Louis, Mo.).
Antibody entrapment in silk films—human polyclonal antibody IgG—Ten ml 1 mg/ml IgG mixed with 167 ml 6% silk solution make the IgG concentration in silk film mg/g silk. 100 μl of mixed IgG solution was added to each well of 96 well plate which was placed in a fume hood with cover opened overnight. The dried film was either treated or not treated with methanol. For methanol treatment, the wells were immersed in 90% methanol solution for 5 min and dried in the fume hood. All dry 96 well plates were then stored at 4° C., room temperature, and 37° C. (
Anti-IL-8 monoclonal antibody (IgG1)—0.5 ml 1 mg/ml IgG1 mixed with 83 ml 6% silk solution make the IgG1 concentration in silk film 0.1 mg/g silk. 50 μl of mixed IgG1 solution was added to a well of 96 well plate which was placed in a fume hood with cover opened overnight. The dried film was either treated or not treated with methanol. For methanol treatment, the wells were immersed in 90% methanol solution for 5 min and dried in the fume hood. All dry 96 well plates were then stored at 4° C., room temperature, and 37° C. (
Antibody measurement—Five wells prepared at the same condition were measured for statistic. Pure silk (without antibody) was used as a control.
For non methanol-treated samples, 100 μl of PBS buffer, pH 7.4, was added to the well which was further incubated at room temperature for 30 min to allow the film to completely dissolve. Aliquot of solution was then subjected to antibody measurement. For methanol-treated samples, 100 μl HFIP was added into each well which was further incubated at room temperature for 2 hours to allow the film completely dissolve. The silk HFIP solution was dried in a fume hood overnight. The follow step was the same as non methanol-treated samples, added PBS buffer and pipette the solution for antibody measurement.
ELISA—Polystyrene (96-well) microtitre plate was coated with 100 μL of antigen anti-Human IgG-affinity at a concentration of 10 μg/mL prepared in antigen coating buffer (bicarbonate buffer, 50 mM, pH 9.6) and then incubated overnight storage at room temperature. The wells were then washed three times with TBS-T buffer. The unoccupied sites were blocked with 1% BSA in TBS (200 μL each well) followed by incubation for 30 minutes at room temperature. The wells were then washed three times with TBS-T. The test and control wells were then diluted with 100 μL of serially diluted serum. Each dilution was in TBS buffer. Serially diluted blanks corresponding to each dilution were also present. The plate was then incubated for 1 h at room temperature. The plate was washed again with TBS-T buffer (five times). Bound antibodies were assayed with an appropriate conjugate of anti-human IgG-HRP (1:100,000), 100 μL of it was coated in each well and kept at room temperature for 1 hour. Washing of the plate with TBS-T (five times) was followed by addition of 100 μL TMB in each well and incubation at room temperature for 5-20 min. The absorbance of each well was monitored at 450 nm on a VersaMax microplate reader (Molecular devices, Sunnyvale, Calif.).
This application claims the benefit of priority of U.S. Provisional Application Ser. No. 60/856,297 filed on Nov. 3, 2006, entitled “Biopolymer Devices and Methods for Manufacturing the Same.” This application also claims the benefit of priority of U.S. Provisional Application Ser. No. 60/935,459, filed on Aug. 14, 2007, entitled “Biopolymer Photonic Crystal and Method of Manufacturing the Same.” This application claims the benefit of priority of U.S. patent application Ser. No. 12/513,384, filed May 4, 2009, which is a 35 U.S.C. 371 National Stage of International Application No. PCT/US2007/083600, filed Nov. 5, 2007, entitled “Biopolymer Photonic Crystal and Method of Manufacturing the Same.” The contents of each of which are hereby incorporated by reference in their entirety.
The invention was made with government support under grant number FA95500410363 awarded by the Air Force Office of Scientific Research. The government has certain rights in this invention.
Number | Name | Date | Kind |
---|---|---|---|
4676640 | Briggs | Jun 1987 | A |
4977902 | Sekino et al. | Dec 1990 | A |
4999295 | Asakura et al. | Mar 1991 | A |
5244799 | Anderson | Sep 1993 | A |
5252285 | Lock | Oct 1993 | A |
5427096 | Bogusiewicz et al. | Jun 1995 | A |
5474915 | Dordick et al. | Dec 1995 | A |
5512218 | Gresser et al. | Apr 1996 | A |
5552270 | Khrapko et al. | Sep 1996 | A |
6134045 | Jiang et al. | Oct 2000 | A |
6150491 | Akkara | Nov 2000 | A |
6284418 | Trantolo | Sep 2001 | B1 |
6753064 | Nakama et al. | Jun 2004 | B1 |
6924503 | Cheng et al. | Aug 2005 | B2 |
6989897 | Chan et al. | Jan 2006 | B2 |
6992325 | Huang | Jan 2006 | B2 |
7223609 | Anvar et al. | May 2007 | B2 |
7267958 | Dordick et al. | Sep 2007 | B2 |
7476398 | Doillon et al. | Jan 2009 | B1 |
7498802 | Takahata | Mar 2009 | B2 |
7713778 | Li et al. | May 2010 | B2 |
8005526 | Martin et al. | Aug 2011 | B2 |
8348974 | Asakura | Jan 2013 | B2 |
8529835 | Kaplan et al. | Sep 2013 | B2 |
20010002417 | Akkara et al. | May 2001 | A1 |
20010003043 | Metspalu et al. | Jun 2001 | A1 |
20030020915 | Schueller et al. | Jan 2003 | A1 |
20030203366 | Lim et al. | Oct 2003 | A1 |
20030214057 | Huang | Nov 2003 | A1 |
20040001299 | van Haaster et al. | Jan 2004 | A1 |
20040029241 | Hahn et al. | Feb 2004 | A1 |
20040081384 | Datesman et al. | Apr 2004 | A1 |
20040229349 | Daridon | Nov 2004 | A1 |
20050008675 | Bhatia et al. | Jan 2005 | A1 |
20050151966 | Packirisamy et al. | Jul 2005 | A1 |
20050169962 | Bhatia et al. | Aug 2005 | A1 |
20050194365 | Li | Sep 2005 | A1 |
20050208469 | Daunert et al. | Sep 2005 | A1 |
20050213868 | Cunningham | Sep 2005 | A1 |
20050217990 | Sibbett et al. | Oct 2005 | A1 |
20050276791 | Hansford et al. | Dec 2005 | A1 |
20060024813 | Warthoe | Feb 2006 | A1 |
20060042822 | Azeyanagi et al. | Mar 2006 | A1 |
20060091571 | Akutsu et al. | May 2006 | A1 |
20060111517 | Feucht et al. | May 2006 | A1 |
20060134606 | Montagu | Jun 2006 | A1 |
20060141617 | Desai et al. | Jun 2006 | A1 |
20060177479 | Giachelli et al. | Aug 2006 | A1 |
20060178655 | Santini et al. | Aug 2006 | A1 |
20060226575 | Maghribi et al. | Oct 2006 | A1 |
20060236436 | Li et al. | Oct 2006 | A1 |
20070007661 | Burgess et al. | Jan 2007 | A1 |
20070009968 | Cunningham et al. | Jan 2007 | A1 |
20070026064 | Yoder et al. | Feb 2007 | A1 |
20070031607 | Dubson et al. | Feb 2007 | A1 |
20070042505 | Israel et al. | Feb 2007 | A1 |
20070058254 | Kim | Mar 2007 | A1 |
20070073130 | Finch et al. | Mar 2007 | A1 |
20070178240 | Yamazaki et al. | Aug 2007 | A1 |
20070224677 | Neumann | Sep 2007 | A1 |
20070233208 | Kurtz et al. | Oct 2007 | A1 |
20070275030 | Muratoglu et al. | Nov 2007 | A1 |
20080019925 | Begleiter | Jan 2008 | A1 |
20080038236 | Gimble et al. | Feb 2008 | A1 |
20080152281 | Lundquist et al. | Jun 2008 | A1 |
20080203431 | Garcia et al. | Aug 2008 | A1 |
20080239755 | Parker et al. | Oct 2008 | A1 |
20080288037 | Neysmith et al. | Nov 2008 | A1 |
20090028910 | DeSimone et al. | Jan 2009 | A1 |
20090208555 | Kuttler et al. | Aug 2009 | A1 |
20100028451 | Kaplan et al. | Feb 2010 | A1 |
20100046902 | Kaplan et al. | Feb 2010 | A1 |
20100063404 | Kaplan et al. | Mar 2010 | A1 |
20100068740 | Kaplan et al. | Mar 2010 | A1 |
20100070068 | Kaplan et al. | Mar 2010 | A1 |
20100120116 | Kaplan et al. | May 2010 | A1 |
20110135697 | Omenetto et al. | Jun 2011 | A1 |
20120034291 | Amsden et al. | Feb 2012 | A1 |
20130323811 | Kaplan et al. | Dec 2013 | A1 |
20140205797 | Kaplan et al. | Jul 2014 | A1 |
20140349380 | Omenetto et al. | Nov 2014 | A1 |
Number | Date | Country |
---|---|---|
0245509 | Nov 1987 | EP |
1025988 | Aug 2000 | EP |
1116987 | Jul 2001 | EP |
1166987 | Jan 2002 | EP |
1209280 | May 2002 | EP |
1467224 | Oct 2004 | EP |
60-142259 | Jul 1985 | JP |
60-155129 | Aug 1985 | JP |
H01-135853 | May 1989 | JP |
01280242 | Nov 1989 | JP |
02-086799 | Mar 1990 | JP |
11-042106 | Feb 1999 | JP |
H11-123791 | May 1999 | JP |
H11-183854 | Jul 1999 | JP |
2000-019119 | Jan 2000 | JP |
2000-096490 | Apr 2000 | JP |
2000-143472 | May 2000 | JP |
2000-180969 | Jun 2000 | JP |
2001-147301 | May 2001 | JP |
2001-280242 | Oct 2001 | JP |
2002-287377 | Oct 2002 | JP |
2003-195001 | Jul 2003 | JP |
2003-322729 | Nov 2003 | JP |
2004-162209 | Jun 2004 | JP |
2004-307661 | Nov 2004 | JP |
2005-031724 | Feb 2005 | JP |
2005-530983 | Oct 2005 | JP |
2006-119424 | May 2006 | JP |
2006-241450 | Sep 2006 | JP |
2011-123791 | Jun 2011 | JP |
05-039368 | Oct 2012 | JP |
20060027113 | Mar 2006 | KR |
20070060822 | Jun 2007 | KR |
20080069553 | Jul 2008 | KR |
WO-9315244 | Aug 1993 | WO |
WO-9605510 | Feb 1996 | WO |
WO-0031752 | Jun 2000 | WO |
WO-0110464 | Feb 2001 | WO |
WO-0185637 | Nov 2001 | WO |
WO-03038033 | May 2003 | WO |
WO-2004000915 | Dec 2003 | WO |
WO-2004071949 | Aug 2004 | WO |
WO-2004092250 | Oct 2004 | WO |
WO-2005012606 | Feb 2005 | WO |
WO-2005019503 | Mar 2005 | WO |
WO-2005031724 | Apr 2005 | WO |
WO-2005103670 | Nov 2005 | WO |
WO-2005123114 | Dec 2005 | WO |
WO-2006020507 | Feb 2006 | WO |
WO-2008004356 | Jan 2008 | WO |
WO-2008118211 | Oct 2008 | WO |
WO-2008127402 | Oct 2008 | WO |
WO-2008127403 | Oct 2008 | WO |
WO-2008127404 | Oct 2008 | WO |
WO-2008127405 | Oct 2008 | WO |
WO-2008140562 | Nov 2008 | WO |
WO-2009061823 | May 2009 | WO |
WO-2010042798 | Apr 2010 | WO |
WO-2010059963 | May 2010 | WO |
WO-2010126640 | Nov 2010 | WO |
Entry |
---|
A. P. Joglekar et al., A Study of the Deterministic Character of Optical Damage by Femtosecond Laser Pulses and Applications to Nanomachining, 77 APPL. PHYS. B 25-30 (2003). |
Y. Liu et al., 3D Femtosecond Laser Patterning of Collagen for Directed Cell Attachment, 26 Biomaterials 4597-4605 (2005). |
Anderson, J. et al., Bioactive Silk-Like Protein Polymer Films on Silicon Devices, Materials Research Society Synthesis and Thermoelectric Properties, 330:171-177 (1994). |
Bai, J. et al., Regenerated spider silk as a new biomaterial for MEMS, Biomed Microdevices, 8:317-323 (2006). |
Chrisey, D.B. et al., Laser Deposition of Polymer and Biomaterial Films, Chem. Rev 103(2):553-576 (2003). |
Extended European Search Report for EP 09767706.6, 6 pages (Jan. 8, 2013). |
Extended European Search Report for EP 13156510.3, 7 pages (Oct. 11, 2013). |
Extended European Search Report for EP 13156523.6, 9 pages (Dec. 18, 2013). |
Fukuoka T. et al., Enzymatic Polymerization of Tyrosine Derivatives. Peroxidase—and Protease-Catalyzed Synthesis of Poly(tyrosine)s with Different Structures, Biomacromolecules 3(4):768-774 (2002). |
International Search Report for PCT/US2007/083600, 3 pages (Nov. 5, 2008). |
International Search Report for PCT/US2007/083620, 3 pages (Dec. 5, 2008). |
International Search Report for PCT/US2007/083642, 3 pages (Nov. 5, 2008). |
International Search Report for PCT/US2007/083646, 4 pages (Dec. 15, 2008). |
International Search Report for PCT/US2011/032195, 3 pages (Oct. 27, 2011). |
International Search Report for PCT/US2007/083605, mailed Dec. 15, 2008, 6 pages. |
International Search Report for PCT/US2007/083634, mailed Nov. 5, 2008, 5 pages. |
International Search Report for PCT/US/2007/083639, mailed Dec. 12, 2008, 5 pages. |
International Search Report of PCT/US2008/082487, mailed Feb. 27, 2009, 3 pages. |
International Search Report of PCT/US2009/047751, mailed Feb. 2, 2010, 3 pages. |
International Search Report of PCT/US2010/022701, mailed Mar. 31, 2010, 2 pages. |
International Search Report of PCT/US2010/024004, mailed Nov. 26, 2010, 5 pages. |
International Search Report of PCT/US2010/042585, mailed May 25, 2011, 8 pages. |
International Search Report of PCT/US2010/047307, mailed Apr. 28, 2011, 3 pages. |
International Search Report of PCT/US2010/050468, mailed Jan. 6, 2011, 3 pages. |
International Search Report of PCT/US2011/028094, mailed Jul. 14, 2011, 4 pages. |
International Search Report of PCT/US2011/041002, 4 pages (Feb. 29, 2012). |
IPRP for PCT/US2007/083642, 6 pages (May 5, 2009). |
IPRP of PCT/US2007/083600, mailed May 5, 2009, 6 pages. |
IPRP of PCT/US2007/083605, mailed May 5, 2009, 10 pages. |
IPRP of PCT/US2007/083620, mailed May 5, 2009, 6 pages. |
IPRP of PCT/US2007/083634, mailed May 5, 2009, 6 pages. |
IPRP of PCT/US2007/083639, mailed May 5, 2009, 6 pages. |
IPRP of PCT/US2007/083646, mailed May 5, 2009, 10 pages. |
IPRP of PCT/US2008/082487, mailed May 11, 2010, 10 pages. |
IPRP of PCT/US2009/047751, mailed Dec. 18, 2010, 5 pages. |
IPRP of PCT/US2010/022701, mailed Aug. 2, 2011, 5 pages. |
IPRP of PCT/US2010/024004, mailed Aug. 16, 2011, 6 pages. |
IPRP of PCT/US2010/042585, mailed Jan. 24, 2012, 6 pages. |
IPRP of PCT/US2010/047307, mailed Mar. 6, 2012, 5 pages. |
Jiang, W. et al, Silicon and Polymer Nanophotonic Devices Based on Photonic Crystals, Proceedings of the International Society of Optical Engineering, 6124(1):612410-1(2006). |
Jin, H.J. et al., Water-Stable Silk Films with Reduced βSheet Content, Advanced Functional Materials, 15:1241-1247 (2005). |
Kouba et al., Fabrication of Nanoimprint Stamps for Photonic Crystals, Journal of Physics: Conference Series, 34(1):897-903 (2006). |
Lawrence, B.D. et al., Bioactive silk protein biomaterial systems for optical devices, Biomacromolecules, 9:1214-1220 (2008). |
Min, B.M. et al., Regenerated Silk Fibroin Nanofibers: Water Vapor-Induced Structural Changes and Their Effects on the Behavior of Normal Human Cells, Macromol. Biosci., 6(4):285-292 (2006). |
Minoura, N. et al., Attachment and Growth of Cultured Fibroblast Cells on Silk Protein Matrices, J. Biomed. Mater. Res. 29(10):1215-1221 (1995). |
Notification of Transmittal of International Search Report and the Written Opinion of PCT/US2011/032195, mailed Oct. 27, 2011, 2 pages. |
Partial European Search Report for EP 13156523.6, 6 pages (Aug. 28, 2013). |
Ramanujam, P.S., Optical Fabrication of Nano-Structured Biopolymer Surfaces, Opt. Mater. 27:1175-1177 (2005). |
Tamada, Y., New Process to Form a Silk Fibroin Porous 3-D Structure, Biomacrocolecules, 6:3100-3106 (2005). |
Tu, D. et al., A ZEP520-LOR Bilayer Resist Lift-Off Process By E-Beam Lithography For Nanometer Pattern Transfer, Proceedings of the 7th IEEE Conference on Nanotechnology, 624-627 (2007). |
Verma, M.K. et al., Embedded Template-Assisted Fabrication of Complex Microchannels in PDMS and Design of a Microfluidic Adhesive, Langmuir, 22(24) 10291-10295 (2006). |
Wang, L. et al., Fabrication Of Polymer Photonic Crystal Superprism Structures Using Polydimethylsiloxane Soft Molds Journal of Applied Physics, 101(11):114316/1-6 (2007). |
Wang, X. et al., Biomaterial coatings by stepwise deposition of silk fibroin, Langmuir, 21(24):11335-41 (2005). |
Written Opinion for PCT/US2011/032195, 5 pages (Oct 27, 2011). |
Written Opinion for PCT/US2007/083600, 5 pages (Nov. 5, 2008). |
Written Opinion for PCT/US2007/083620, 5 pages (Dec. 5, 2008). |
Written Opinion for PCT/US2007/083642, 5 pages (Nov. 5, 2008). |
Written Opinion for PCT/US2007/083646, 9 pages (Dec. 15, 2008). |
Written Opinion of PCT/US2007/083605, mailed Dec. 15, 2008, 9 pages. |
Written Opinion of PCT/US2007/083634, mailed Nov. 5, 2008, 5 pages. |
Written Opinion of PCT/US2007/083639, mailed Dec. 12, 2008, 5 pages. |
Written Opinion of PCT/US2008/082487, mailed Feb. 27, 2009, 9 pages. |
Written Opinion of PCT/US2009/047751, mailed Feb. 2, 2010, 4 pages. |
Written Opinion of PCT/US2010/022701, mailed Mar. 31, 2010, 4 pages. |
Written Opinion of PCT/US2010/024004, mailed Nov. 26, 1010, 5 pages. |
Written Opinion of PCT/US2010/042585, mailed May 25, 2011, 5 pages. |
Written Opinion of PCT/US2010/047307, mailed on Apr. 28, 2011, 4 pages. |
Xu, P. and Kaplan, D.L., Horseradish peroxidase catalyzed polymerization of tyrosine derivatives for nanoscale surface patterning, Journal of Macromolecular Science, Part A: Pure and Applied Chemistry, 41(12):1437-1445 (2004). |
Yang, L.J. et al., Fabrication of SU-8 embedded microchannels with circular cross-section. |
International Journal of Machine Tools & Manufacturing, 44:1109-1114 (2004). |
Number | Date | Country | |
---|---|---|---|
20140205797 A1 | Jul 2014 | US |
Number | Date | Country | |
---|---|---|---|
60935459 | Aug 2007 | US | |
60856297 | Nov 2006 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12513384 | US | |
Child | 14065369 | US |